Accure Acne, Inc.

Accure Acne, Inc. manufactures the Accure Acne Laser System, an FDA-cleared medical device for the treatment of mild to severe inflammatory acne vulgaris. The system utilizes a proprietary 1726 nm laser with "treat-to-temperature" technology designed to precisely target overactive sebaceous glands, the root cause of acne. The treatment protocol consists of four sessions spaced one month apart, performed exclusively in dermatology offices. Clinical data indicate an average 70% reduction in acne lesions at 6 months post-treatment completion, with up to 95% of patients reporting very or extremely high satisfaction. The device has been tested across all Fitzpatrick skin types with consistent outcomes. Accure positions itself as a non-systemic alternative to oral acne medications, appealing to patients seeking to avoid systemic drug side effects. The company markets directly to dermatologists and consumers, offering provider locator services, patient education resources, and financing options for practice acquisition. Manufacturing and regulatory credentials include FDA clearance for acne treatment indication.